Stocktoria
AstraZeneca PLC AZN.L
GB · London Stock Exchange · XLON · stock · Healthcare · website
AstraZeneca PLC financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $58.7B | $54.1B | $45.8B | $44.4B |
| Gross profit | $48.1B | $43.9B | $37.5B | $32.0B |
| R&D expense | $14.2B | $13.6B | $10.9B | $9.8B |
| SG&A expense | $20.8B | $20.2B | $18.2B | $18.0B |
| Operating income | $13.3B | $10.3B | $8.7B | $4.5B |
| Interest expense | $1.6B | $1.7B | $1.6B | $1.3B |
| Income tax | $2.2B | $1.6B | $938.0M | -$792.0M |
| Net income | $10.2B | $7.0B | $6.0B | $3.3B |
| EPS (diluted) | $6.54 | $4.50 | $3.81 | $2.11 |
| Operating cash flow | $14.6B | $11.9B | $10.3B | $9.8B |
| Free cash flow | $8.7B | $7.3B | $6.6B | $7.2B |
| Cash & equivalents | $5.7B | $5.5B | $5.8B | $6.2B |
| Inventory | $6.6B | $5.3B | $5.4B | $4.7B |
| Total assets | $114.1B | $104.0B | $101.1B | $96.5B |
| Total liabilities | $65.4B | $63.2B | $62.0B | $59.4B |
| Shareholders' equity | $48.7B | $40.8B | $39.1B | $37.0B |
Growth · year-over-year · Revenue CAGR 9.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +8.6% | +18.0% | +3.3% | — |
| Net income growth | +45.3% | +18.1% | +81.1% | — |
| EPS growth | +45.3% | +18.1% | +80.6% | — |
| Free cash flow growth | +19.2% | +10.8% | -9.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.